SCHEMBL21747397

SCHEMBL21747397

COc1ccc(-c2cccn2C2(C(=O)O)CCCC2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.40
TRPV1 Q8NER1 1/20 0.40
CTSK P43235 3/20 0.39
LMNA P02545 1/20 0.39
P2RX3 P56373 1/20 0.39
ALDH1A1 P00352 5/20 0.39
HTT P42858 1/20 0.39
KDM4E B2RXH2 2/20 0.38
SLC6A3 Q01959 1/20 0.38
HPGD P15428 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
USP2 O75604 2/20 0.37
CYP2C9 P11712 2/20 0.37
HIF1A Q16665 2/20 0.37
HSD17B10 Q99714 2/20 0.37
CYP2C19 P33261 2/20 0.37
TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21747377 0.99 FAAH (0.42) FAAHTRPV1CTSKLMNAP2RX3
SCHEMBL21747267 0.87 ALDH1A1 (0.37) FAAHTRPV1CTSKLMNAP2RX3
SCHEMBL21747276 0.86 ALDH1A1 (0.42) ALDH1A1HTTKDM4EHPGDSMN1; SMN2
SCHEMBL25543982 0.86 P2RX3 (0.37) FAAHTRPV1CTSKLMNAP2RX3
SCHEMBL21747378 0.86 FAAH (0.39) FAAHTRPV1CTSKLMNAP2RX3
SCHEMBL21747422 0.85 ALDH1A1 (0.36) LMNAALDH1A1HTTKDM4EHPGD
SCHEMBL21747303 0.84 ALDH1A1 (0.40) LMNAALDH1A1KDM4ESMN1; SMN2TSHR
SCHEMBL21747254 0.83 ALDH1A1 (0.39) FAAHLMNAALDH1A1KDM4ESMN1; SMN2
SCHEMBL21747351 0.82 ERAP1 (0.36) TRPV1ALDH1A1KDM4ESMN1; SMN2RPA1
SCHEMBL21747407 0.82 HSD11B1 (0.36) FAAHALDH1A1KDM4ECYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11970495-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2024-04-30 US disclosed
US-11945817-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2024-04-02 US disclosed
US-20230257379-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2023-08-17 US disclosed
US-20230257379-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2023-08-17 US disclosed
US-20230257379-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2023-08-17 US disclosed
US-20230242527-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2023-08-03 US disclosed
US-20230242527-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2023-08-03 US disclosed
US-20230242527-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2023-08-03 US disclosed
US-11655249-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2023-05-23 US disclosed
US-11655249-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2023-05-23 US disclosed
US-20210253570-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2021-08-19 US disclosed
US-20210253570-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2021-08-19 US disclosed
CN-113004271-A Indolizine derivative and application thereof in medicine 杭州安道药业有限公司 2021-06-22 CN disclosed
US-11021478-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2021-06-01 US disclosed
US-11021478-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2021-06-01 US disclosed
CN-108484598-B Indolizine derivative and application thereof in medicine 杭州安道药业有限公司 2021-03-02 CN disclosed
US-20200165242-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2020-05-28 US disclosed
US-20200165242-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2020-05-28 US disclosed
EP-3613742-A1 INDOLIZINE DERIVATIVES AND APPLICATION THEREOF IN MEDICINE Kind Pharmaceutical (CN) 2020-02-26 EP disclosed
EP-3613742-A1 INDOLIZINE DERIVATIVES AND APPLICATION THEREOF IN MEDICINE Kind Pharmaceutical (CN) 2020-02-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257379-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE INMT, IDO1, IDO2 FAAH 2999/4885TRPV1 980/4885CTSK 3651/4885
US-11021478-B2 Indolizine derivatives and their application in medicine INMT, IDO1, IDO2 FAAH 2999/4885TRPV1 980/4885CTSK 3651/4885
US-11970495-B2 Indolizine derivatives and their application in medicine INMT, IDO1, IDO2 FAAH 2999/4885TRPV1 980/4885CTSK 3651/4885
US-20230242527-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE INMT, IDO1, IDO2 FAAH 2999/4885TRPV1 980/4885CTSK 3651/4885
US-11945817-B2 Indolizine derivatives and their application in medicine INMT, IDO1, IDO2 FAAH 2999/4885TRPV1 980/4885CTSK 3651/4885
US-20210253570-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE INMT, IDO1, IDO2 FAAH 2999/4885TRPV1 980/4885CTSK 3651/4885
US-11655249-B2 Indolizine derivatives and their application in medicine INMT, IDO1, IDO2 FAAH 2999/4885TRPV1 980/4885CTSK 3651/4885
US-20200165242-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE INMT, IDO1, IDO2 FAAH 2999/4885TRPV1 980/4885CTSK 3651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.